JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

97.71 -7.97

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

97.54

Max

107.19

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+20.89% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.9B

15B

Ankstesnė atidarymo kaina

105.68

Ankstesnė uždarymo kaina

97.71

Naujienos nuotaikos

By Acuity

50%

50%

151 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-05 00:00; UTC

Karštos akcijos

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

2026-02-04 22:55; UTC

Uždarbis

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

2026-02-04 21:44; UTC

Uždarbis

Arm Holdings 3Q Profit Falls Despite Revenue Growth

2026-02-04 21:39; UTC

Uždarbis

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

2026-02-05 00:00; UTC

Uždarbis

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

2026-02-05 00:00; UTC

Uždarbis

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

2026-02-04 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026-02-04 23:45; UTC

Uždarbis

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

2026-02-04 23:32; UTC

Rinkos pokalbiai

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

2026-02-04 22:59; UTC

Įsigijimai, susijungimai, perėmimai

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

2026-02-04 22:30; UTC

Uždarbis

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

2026-02-04 22:30; UTC

Uždarbis

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

2026-02-04 22:21; UTC

Uždarbis

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026-02-04 22:17; UTC

Rinkos pokalbiai

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

2026-02-04 22:15; UTC

Rinkos pokalbiai

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

2026-02-04 22:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2026-02-04 21:53; UTC

Uždarbis

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

2026-02-04 21:51; UTC

Uždarbis

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026-02-04 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-02-04 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-02-04 21:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2026-02-04 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-02-04 21:45; UTC

Uždarbis

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

2026-02-04 21:44; UTC

Uždarbis

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

2026-02-04 21:43; UTC

Uždarbis

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

2026-02-04 21:41; UTC

Uždarbis

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

2026-02-04 21:36; UTC

Rinkos pokalbiai

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

2026-02-04 21:30; UTC

Uždarbis

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026-02-04 21:30; UTC

Uždarbis

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026-02-04 21:30; UTC

Uždarbis

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

20.89% į viršų

12 mėnesių prognozė

Vidutinis 128.33 USD  20.89%

Aukščiausias 175 USD

Žemiausias 105 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

151 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat